People with bipolar disorder who take the diabetes and weight-loss medication semaglutide experience a significantly lower risk of psychiatric hospitalization, according to a nationwide study published in the journal Acta Psychiatrica Scandinavica on June 21, 2026. Researchers analyzed health registry data from Sweden covering nearly 15,000 patients and found a 21 percent reduction in hospitalizations during periods when patients used the medication compared to times when they did not.
Semaglutide Lowers Psychiatric Hospitalization Risk
Led by researchers including Professor Mark Taylor of Griffith University’s School of Medicine and Dentistry, the study examined 15 years of nationwide health data from 2009 to 2024. The analysis tracked patients with bipolar disorder who were prescribed glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as Ozempic or Wegovy. According to Professor Taylor, individuals taking semaglutide had significantly lower rates of psychiatric hospitalization than during periods when they were off the medication, amounting to an overall 21 percent risk reduction.
Bipolar disorder affects an estimated 37 million people worldwide, according to World Health Organization data cited in the research. The condition is characterized by recurring episodes of depression and unusually elevated or irritable moods that often require inpatient psychiatric care during severe phases. Diabetes and obesity also occur frequently among this patient population, pointing to potential overlapping biological pathways involving metabolism, cellular stress, and inflammation.
Investigating Mechanisms Beyond Metabolism
GLP-1 medications mimic a naturally occurring hormone that regulates blood sugar, digestion, and appetite. Scientists are increasingly examining whether this same signaling system influences neurological processes. The study authors suggest that GLP-1 receptor agonists may help reduce inflammation and cellular stress in the brain, which could theoretically stabilize moods and prevent relapses in psychiatric patients.
“The findings add to growing evidence that GLP-1 receptor agonists may have benefits beyond diabetes and obesity treatment and could represent a promising new avenue for bipolar research,” Professor Taylor stated. However, the researchers noted that the observed mental health benefit was specific to semaglutide. Other medications in the same drug class, including liraglutide and dulaglutide, did not show the same association with reduced psychiatric hospitalizations.
Next Steps for Clinical Research
While the registry data establish a correlation between semaglutide use and fewer psychiatric hospitalizations, the research team recommends conducting randomized controlled trials to test whether semaglutide directly improves psychiatric outcomes and to determine if the medication could eventually serve a role in bipolar disorder treatment protocols.
Keep reading